Indian Journal of Nuclear Medicine

LETTER TO EDITOR
Year
: 2013  |  Volume : 28  |  Issue : 3  |  Page : 187--188

Bone metastasis from a neuroendocrine tumor detected by 99m-technetium-hydrazinonicotinyl- Tyr3-octreotide single-photon emission computed tomography/computed tomography


Koramadai Karuppusamy Kamaleshwaran1, Paul Vannan Subramanian2, Sudhakar Natarajan2, Vyshak Mohanan1, Ajit Sugunan Shinto1,  
1 Department of Nuclear Medicine and PET/CT,Kovai Medical Centre and Hospital Limited,Coimbatore, India
2 Department of Oncology, Comprehensive Cancer Care Centre,Kovai Medical Centre and Hospital Limited,Coimbatore, India

Correspondence Address:
Koramadai Karuppusamy Kamaleshwaran
Department of Nuclear Medicine,PET/CT and Radionuclide Therapy,Comprehensive Cancer Care Centre,Kovai Medical Centre and Hospital Limited, Coimbatore 641 014
India




How to cite this article:
Kamaleshwaran KK, Subramanian PV, Natarajan S, Mohanan V, Shinto AS. Bone metastasis from a neuroendocrine tumor detected by 99m-technetium-hydrazinonicotinyl- Tyr3-octreotide single-photon emission computed tomography/computed tomography.Indian J Nucl Med 2013;28:187-188


How to cite this URL:
Kamaleshwaran KK, Subramanian PV, Natarajan S, Mohanan V, Shinto AS. Bone metastasis from a neuroendocrine tumor detected by 99m-technetium-hydrazinonicotinyl- Tyr3-octreotide single-photon emission computed tomography/computed tomography. Indian J Nucl Med [serial online] 2013 [cited 2019 Dec 9 ];28:187-188
Available from: http://www.ijnm.in/text.asp?2013/28/3/187/119520


Full Text

Sir,

Neuroendocrine tumors (NETs) are neoplasms originating from the neural crest and consequently can be localized in different organs. According to Rufini et al., [1] the presence of neuroamine uptake mechanisms and/or peptide receptors on the cell membrane of these tumors is the basis of the clinical use of specific radiolabeled ligands, both for imaging and therapy. Technetium-99m (Tc-99m)-ethylenediamine-N, N′-diacetic acid (EDDA)-hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) is a radiopharmaceutical indicated for the diagnosis of tumors overexpressing somatostatin receptors [2] (sstr2) (especially subtype 2, sstr2), which can be imaged with this radiolabeled ligand. [2] HYNIC-TOC single-photon emission computed tomography/computed tomography (SPECT/CT) improve interpretation and allow precise localization of lesions. [3] We report a case of HYNIC-TOC SPECT/CT useful in detecting bone metastasis near urinary bladder activity.

A 58-year-old male with biopsy proven hepatic metastases from NET was sent for localizing primary lesion and any other sites of metastasis. Whole body planar scintigraphy was performed after intravenous injection of 20 mCi (740 Mbq) of Tc-99m-HYNIC-TOC showed photopenic area in the necrotic liver metastasis and also there were two focal uptakes noted in the upper part of right thigh and other below the bladder [Figure 1]. SPECT/CT of the upper thigh including pelvis was performed, which showed a sclerotic lesion in the neck of right femur and additional lesion noted just below the bladder was localized to sclerotic lesion in left pubis [Figure 2] and [Figure 3].{Figure 1}{Figure 2}{Figure 3}

Sstr2 scintigraphy with In-111-octreotide has been one of the standard procedures for imaging NETs. [4] The limitations of this technique are due to the use of In-111 as the radiolabeler with its limited availability, high cost, medium gamma energy leading to suboptimal image resolution and relatively high radiation burden to the patient. [5] 111In-diethylene triamine pentaacetic acid (DTPA)-octreotide SPECT/CT demonstrates that image fusion is clearly superior to SPECT alone, allowing precise localization of lesions and reducing false-positive results. [6] Guggenberg et al., [7] proved that the high specific tumor uptake, rapid blood clearance and predominantly renal excretion as well as improved image quality, lower radiation dose for the patient and daily availability, make Tc-99m-EDDA-HYNIC-TOC a promising candidate for an alternative to 111In-DTPA-octreotide for NET imaging. Although planar and SPECT/CT scans in NETs are reported, increased resolution of SPECT and addition of CT is confirmatory for bone metastasis.

References

1Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-47.
2Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. 99mTc-EDDA/HYNIC-TOC: A new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 2000;27:1318-25.
3Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P, et al. Image fusion analysis of (99m) Tc-HYNIC-Tyr (3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging 2005;32:1440-51.
4Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
5Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: Preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 2000;41:1114-9.
6Castaldi P, Rufini V, Treglia G, Bruno I, Perotti G, Stifano G, et al. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. Radiol Med 2008;113:1056-67.
7Guggenberg EV, Mikolajczak R, Janota B, Riccabona G, Decristoforo C. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis. J Pharm Sci 2004;93:2497-506.